Platelet function testing in clinical practice: Are we ready for it in first-line?;Pruebas de función plaquetaria en la práctica clínica: ¿estamos preparados para que pasen a la primera línea?

Revista Espanola de Cardiologia

Volumn 62, Issue 2, 2009, Pages 113-116

  Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; EDITORIAL; HEART INFARCTION; HUMAN; PROGNOSIS; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PLATELETS; HUMANS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS;

EID: 60649108290     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70151-4     Document Type: Editorial

References (20)

1. Badimón L., and Vilahur G. Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. Rev Esp Cardiol 61 (2008) 501-513
2. Angiolillo D.J., Guzmán L.A., and Bass T.A. Current antiplatelet therapies: benefits and limitations. Am Heart J 156 2 Suppl (2008) S3-S9
3. Angiolillo D.J., and Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 98 (2007) 707-709
4. De Miguel Castro A., Cuellas Ramón C., Diego Nieto A., Samaniego Lampón B., Alonso Rodríguez D., Fernández Vázquez F., et al. La reactividad plaquetaria posterapéutica predice los eventos adversos a largo plazo mejor que la respuesta al clopidogrel en pacientes con síndrome coronario agudo sin elevación del ST. Rev Esp Cardiol 62 (2009) 126-135
5. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
6. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., and Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDAPRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52 (2008) 1128-1133
7. Cuisset T., Hamilos M., Sarma J., Sarno G., Wyffels E., Vanderheyden M., et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 101 (2008) 1700-1703
8. Buch A.N., Singh S., Roy P., Javaid A., Smith K.A., George C.E., et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99 (2007) 1518-1522
9. Alfonso F., and Angiolillo D.J. Platelet function assessment to predict outcomes after coronary interventions: hype or hope?. J Am Coll Cardiol 48 (2006) 1751-1754
10. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
11. Angiolillo D.J., Bernardo E., Sabaté M., Jiménez-Quevedo P., Costa M.A., Palazuelos J., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
12. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Bañuelos C., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
13. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
14. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
15. Valgimigli M., Campo G., De Cesare N., Vranckx P., Hamon M., Angiolillo D.J., et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. Cardiovasc Drugs Ther 22 (2008) 313-320
16. Angiolillo D.J., Capranzano P., Goto S., Aslam M., Desai B., Charlton R.K., et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29 (2008) 2202-2211
17. Lee S.W., Park S.W., Kim Y.H., Yun S.C., Park D.W., Lee C.W., et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 51 (2008) 1181-1187
18. Angiolillo D.J., and Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 156 2 Suppl (2008) S10-S15
19. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
20. Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932